Biotechnological Advances Utilizing Aptamers and Peptides Refining PD-L1 Targeting

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Monoclonal antibodies are established in cancer immunotherapy.
• Limitations of current therapies necessitate novel approaches.
• Programmed death ligand 1 (PD-L1) is a key target in cancer immunotherapy.

Purpose of the Study:

• To review aptamers and peptides for PD-L1 targeting.
• To address the lack of comprehensive reviews on these emerging tools.
• To guide researchers and clinicians on biotechnological advances in PD-L1 targeting.

Main Methods:

• Literature review of aptamers targeting PD-L1.
• Literature review of peptides targeting PD-L1.
• Analysis of recent biotechnological advancements in protein targeting.

Main Results:

• Aptamers and peptides show potential as alternatives to monoclonal antibodies.
• These molecules offer refined targeting capabilities for PD-L1.
• Significant progress has been made in developing aptamer and peptide-based PD-L1 inhibitors.

Conclusions:

• Aptamers and peptides represent a cutting-edge approach in cancer immunotherapy.
• Further research and clinical translation are warranted for these novel agents.
• This review consolidates current knowledge and highlights future directions in PD-L1 targeting.